Whole Body Low Dose CT (WBLDCT) has important advantages as a first-line imaging modality for bone disease assessment in patients with plasma cell disorders and has been included in the 2014 International Myeloma Working Group (IMWG) criteria for multiple myeloma (MM) definition. Nevertheless, standardization guidelines for the optimal use of WBLDCT in MM patients are still lacking, preventing its more widespread use, both in daily practice and clinical trials. The aim of this report by the Bone Group of the IMWG is to provide practical recommendations for the acquisition, interpretation and reporting of WBLDCT in patients with multiple myeloma and other plasma cell disorders.
Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group / Moulopoulos, Lia A; Koutoulidis, Vassilis; Hillengass, Jens; Zamagni, Elena; Aquerreta, Jesus D; Roche, Charles L; Lentzsch, Suzanne; Moreau, Philippe; Cavo, Michele; Miguel, Jesus San; Dimopoulos, Meletios A; Rajkumar, S Vincent; Durie, Brian G M; Terpos, Evangelos; Delorme, Stefan. - In: BLOOD CANCER JOURNAL. - ISSN 2044-5385. - STAMPA. - 8:10(2018), pp. 95-95. [10.1038/s41408-018-0124-1]
Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group
Zamagni, Elena;Cavo, Michele;
2018
Abstract
Whole Body Low Dose CT (WBLDCT) has important advantages as a first-line imaging modality for bone disease assessment in patients with plasma cell disorders and has been included in the 2014 International Myeloma Working Group (IMWG) criteria for multiple myeloma (MM) definition. Nevertheless, standardization guidelines for the optimal use of WBLDCT in MM patients are still lacking, preventing its more widespread use, both in daily practice and clinical trials. The aim of this report by the Bone Group of the IMWG is to provide practical recommendations for the acquisition, interpretation and reporting of WBLDCT in patients with multiple myeloma and other plasma cell disorders.| File | Dimensione | Formato | |
|---|---|---|---|
|
s41408-019-0200-1.pdf
accesso aperto
Tipo:
Versione (PDF) editoriale
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione
313.47 kB
Formato
Adobe PDF
|
313.47 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
